Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19974880 | 0.94 | ALDH1A1 (0.35) | BRD4EPHX1EPHX2KDM4ESMN1; SMN2 | |
| SCHEMBL19974790 | 0.85 | SIGMAR1 (0.40) | EPHX1KDM4ESMN1; SMN2 | |
| SCHEMBL21183548 | 0.85 | EPHX2 (0.39) | EPHX1EPHX2KDM4ESMN1; SMN2 | |
| SCHEMBL19975427 | 0.85 | EPHX1 (0.47) | EPHX1EPHX2KDM4EPKMACHE | |
| SCHEMBL21176247 | 0.85 | KDM4E (0.48) | EPHX1KDM4EPKMSMN1; SMN2 | |
| SCHEMBL19975075 | 0.84 | USP2 (0.38) | EPHX1EPHX2KDM4ESMN1; SMN2 | |
| SCHEMBL19975241 | 0.84 | EPHX1 (0.40) | EPHX1EPHX2SMN1; SMN2 | |
| SCHEMBL19975106 | 0.84 | EPHX1 (0.40) | EPHX1EPHX2SMN1; SMN2 | |
| SCHEMBL19974883 | 0.81 | ALOX15 (0.47) | EPHX1EPHX2 | |
| SCHEMBL19974955 | 0.81 | EPHX1 (0.33) | BRD4EPHX1EPHX2KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | BRD4 2550/4885EPHX1 372/4885EPHX2 1455/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | BRD4 2550/4885EPHX1 372/4885EPHX2 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.